low-power laser in subclinical hypothyroidism

Investigating the effect of low-power laser or photobiomodulation on improvement of laboratory factors and clinical symptoms of subclinical hypothyroidism: a clinical trial study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241008063288N1

Enrollment

Registered

2025-06-04

Start date

2025-05-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical Hypothyroidism. Other hypothyroidism

Interventions

Intervention 1: Intervention Group: This group will receive photobiomodulation (PBM) using a low-level laser device. The PBM procedure is approved by the U.S. Food and Drug Administration (FDA-2022-D-

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: TSH above 5 and normal T3 and T4

Exclusion criteria

Exclusion criteria: autoimmune disease radioactive iodine treatment thyroid surgery TSH above 10 immunosuppressive drug immunoactive drug anti TPO above 100 pregnancy tracheal stenosis radiotherapy Drug interaction

Design outcomes

Primary

Measure	Time frame
Thyroid-stimulating hormone level. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Free thyroxine. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Free triiodothyronine. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Thyroid peroxidase antibody. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Thyroglobulin antibody. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Subclinical hypothyroidism symptom. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ThyPRO-39 questionnaire score.;Systolic blood pressure. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Sphygmomanometer.;Waist Circumference. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Flexible Measuring Tape.;Hip Circumference. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Flexible Measuring Tape.;Cholesterol. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Enzymatic Colorimetric Assay.;Triglycerides. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Enzymatic Colorimetric Assay.;High-Density Lipoprotein. Timepoint: Before the intervention, three and six months after the end of the intervention. Method o	—

Measure

Time frame

Thyroid-stimulating hormone level. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Free thyroxine. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Free triiodothyronine. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Thyroid peroxidase antibody. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Thyroglobulin antibody. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ELISA.;Subclinical hypothyroidism symptom. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: ThyPRO-39 questionnaire score.;Systolic blood pressure. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Sphygmomanometer.;Waist Circumference. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Flexible Measuring Tape.;Hip Circumference. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Flexible Measuring Tape.;Cholesterol. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Enzymatic Colorimetric Assay.;Triglycerides. Timepoint: Before the intervention, three and six months after the end of the intervention. Method of measurement: Enzymatic Colorimetric Assay.;High-Density Lipoprotein. Timepoint: Before the intervention, three and six months after the end of the intervention. Method o

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Seyedian

Shahid Beheshti University of Medical Sciences

zahra.seyyedian@gmail.com+98 990 168 1056

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026